UK fol­lic­u­lar lym­phoma pa­tients set to get non-chemother­a­py ther­a­py as NICE backs Revlim­id com­bo

That was fast!

UK’s cost-ef­fec­tive­ness agency NICE has en­dorsed the use of Cel­gene’s (now Bris­tol-My­ers’) block­buster can­cer ther­a­py Revlim­id for pa­tients with fol­lic­u­lar lym­phoma who have un­der­gone pre­vi­ous treat­ment, about two months af­ter the drug in com­bi­na­tion with Roche’s MabThera se­cured ap­proval from the EU reg­u­la­tor.

In con­trast, NICE backed Revlim­id as the first line of de­fense in cer­tain pa­tients with mul­ti­ple myelo­ma about four years af­ter Eu­ro­pean ap­proval was sanc­tioned.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER